Discounted Cash Flow Rating

Strong Sell

Return on Equity Rating

Strong Sell

Debt to Equity Rating

Strong Sell

Price to Earnings Rating

Strong Sell

Analyst Rating

Strong Sell

Simple Moving Average

Strong Sell

Exponential Moving Average

Strong Sell

Relative Strength Index

Buy

Standard Deviation

Strong Buy

Williams %R

Strong Buy

Average Directional Index

Strong Sell

Insider Trading

Neutral

Wall Street Data Solutions Rating

Sell

C

Evaxion Biotech A/S American Depositary Share (EVAX)

https://www.evaxion-biotech.com

Evaxion Biotech AS is a clinical-stage biotech company that aspires to the exploration of artificial intelligence, or AI, to develop immunotherapies with improved efficacy when compared to currently marketed products for patients with unmet medical needs. Its pipeline programs are derived from its proprietary AI platforms, PIONEER, EDEN, RAVEN, and ObsERV. The company is utilizing these AI platforms to build a drug development pipeline. Its product candidates are; EVX-01 and EVX-02, for the treatment of various cancers, and the third candidate is cancer immunotherapy, EVX-03, for the treatment of various cancers including non-small-cell-lung-cancer, or NSCLC, is in pre-clinical development.

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

02/05/2021

Market Cap

14,610,116

Shares Outstanding

27,810,000

Weighted SO

37,906,996

Total Employees

N/A

Upcoming Earnings

08/16/2024

Beta

-0.2740

Last Div

0.0000

Range

2.26-13.61

Chg

0.0900

Avg Vol

42137

Mkt Cap

14610116

Exch

NASDAQ

Country

DK

Phone

45 53 53 18 50

DCF Diff

4.7924

DCF

-1.7124

Div Yield

0.0000

P/S

52.4855

EV Multiple

-1.2546

P/FV

13.3005

Div Yield %

0.0000

P/E

-1.0938

PEG

-0.0634

Payout

0.0000

Current Ratio

2.8003

Quick Ratio

2.8003

Cash Ratio

2.0919

DSO

3549.6084

DIO

0.0000

Op Cycle

0.0000

DPO

0.0000

CCC

0.0000

Gross Margin

1.0000

Op Margin

-68.7053

Pretax Margin

-57.5830

Net Margin

-54.7394

Eff Tax Rate

0.0492

ROA

-1.0004

ROE

0.6725

ROCE

-1.6761

NI/EBT

0.9506

EBT/EBIT

0.8381

EBIT/Rev

-68.7053

Debt Ratio

0.5738

D/E

6.9745

LT Debt/Cap

0.8683

Total Debt/Cap

0.8746

Int Coverage

-7.4315

CF/Debt

-0.7320

Equity Multi

12.1556

Rec Turnover

0.1028

Pay Turnover

0.0000

Inv Turnover

0.0000

FA Turnover

0.0713

Asset Turnover

0.0183

OCF/Share

-1.1822

FCF/Share

-1.1940

Cash/Share

1.4772

OCF/Sales

-22.9806

FCF/OCF

1.0100

CF Coverage

-0.7320

ST Coverage

-13.4105

CapEx Coverage

-99.9531

Div&CapEx Cov

-99.9531

P/BV

13.3005

P/B

13.3005

P/S

52.4855

P/E

-1.0938

P/FCF

-2.2613

P/OCF

-2.6053

P/CF

-2.6053

PEG

-0.0634

P/S

52.4855

EV Multiple

-1.2546

P/FV

13.3005

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Jan 22, 16:30 Evaxion Announces Completion of ADS Ratio Change GlobeNewswire Inc. Jan 09, 04:43 Evaxion annonce un plan visant à mettre en œuvre la modification du ratio de ses ADS GlobeNewswire Inc. Jan 09, 04:43 Evaxion kündigt Plan zur Änderung des ADS-Verhältnisses an GlobeNewswire Inc. Jan 08, 08:30 Evaxion Announces Plan to Implement ADS Ratio Change GlobeNewswire Inc. Dec 22, 15:13 Evaxion Biotech gibt Abschluss einer Privatplatzierung bekannt GlobeNewswire Inc. Dec 22, 15:13 Clôture du financement par placement privé pour Evaxion Biotech GlobeNewswire Inc. Dec 22, 15:13 Evaxion Biotech gibt Abschluss einer Privatplatzierung bekannt GlobeNewswire Inc. Dec 22, 15:13 Clôture du financement par placement privé pour Evaxion Biotech GlobeNewswire Inc. Dec 21, 16:30 Evaxion Biotech Announces Closing of Private Placement GlobeNewswire Inc. Dec 20, 03:20 Un financement par placement privé pour Evaxion Biotech GlobeNewswire Inc. Dec 20, 03:20 Evaxion Biotech gibt Finanzierung per Privatplatzierung bekannt GlobeNewswire Inc. Dec 20, 03:20 Un financement par placement privé pour Evaxion Biotech GlobeNewswire Inc. Dec 20, 03:20 Evaxion Biotech gibt Finanzierung per Privatplatzierung bekannt GlobeNewswire Inc. Dec 19, 09:25 Evaxion Biotech Announces Private Placement Financing GlobeNewswire Inc. Nov 29, 08:55 Evaxion stellt potenziell bahnbrechendes Konzept für AI-Immunology™-gestützen Präzisions-Krebsimpfstoff vor GlobeNewswire Inc. Nov 29, 08:55 Evaxion va lever le voile sur un concept potentiellement révolutionnaire de vaccin précis contre le cancer alimenté par sa plateforme IA-Immunology™ GlobeNewswire Inc. Nov 16, 08:52 Evaxion präsentiert Proof-of-Principle für sein einzigartiges KI-Modell zur Vorhersage des Ansprechens auf Krebsimmuntherapie GlobeNewswire Inc. Nov 16, 08:52 Evaxion présente la preuve de concept de son modèle unique d’IA prédisant les réponses à l’immunothérapie du cancer GlobeNewswire Inc. Nov 07, 10:15 Evaxion présente les dernières données cliniques de la phase II d’EVX-01 à l’occasion d’un webinaire organisé en présence du leader d’opinion Adnan Khattak GlobeNewswire Inc. Nov 07, 10:15 Evaxion präsentiert neueste klinische Daten der Phase II von EVX-01 in einem Webinar mit dem Key Opinion Leader Adnan Khattak

Revenue Product Segmentation